Explore the latest projects funded through our funding platform that aims to speed up the translation of biomedical discoveries into commercially viable diagnostics, devices, therapeutics and tools to improve health and patient care.
A team of Rutgers researchers merged their ideas and technology with the support of research mentors to get the needed funds for developing a novel device capable of detecting the presence of viruses like SARS-CoV-2 in one’s breath.
This project will develop a biomedical technology called Immuno-Dx, whose value proposition lies in its ability to provide vital information about patients’ immune response to infections, and to fulfill unmet need for personalized diagnostics of septic patients in emergency department (ED) settings.
Our project aims to revolutionize peri-implantitis treatment by developing an innovative electrotherapy device designed to restore the passivation layer of titanium implants. By targeting the root cause of implant degradation and associated inflammation, we seek to enhance the longevity and success of dental implants and improve patient outcomes.
Rutgers researchers have developed an AI-based system to prevent iatrogenic ureteral injury in gynecologic and colorectal surgeries. The technology continuously tracks surgical instruments, providing real-time alerts or movement halts near the ureter. Platform-independent, it enhances intraoperative safety and surgeon control, reducing complications in complex cases with distorted anatomy.
Chlamydiae are common and important human pathogens. This HealthAdvance grant will apply a novel technology to develop a safe and effective life attenuated Chlamydia vaccine. Our vaccines will drastically reduce health and socioeconomic burdens of chlamydial diseases in women and men.
We have developed a novel, first-in-class GSX1 gene therapy that promotes the regeneration of spinal cord tissue, resulting in dramatic functional recovery in an animal model of spinal cord injury (SCI).
Many bacterial diseases are becoming more deadly as bacteria develop resistance to treatment with antibiotics. The proposed work describes an innovative path to identifying novel antibiotics.
Quantum Click is a software capable of formulating new drug candidates by screening billions of compounds virtually. Due to the exceptionally high accuracy, Quantum Click provides robust predictions of drug candidate-protein target interactions.
The long-term goal of this project is to develop a vaccine using centanamycin for DNA viruses where no drug or vaccine is available. Our study offers an attractive opportunity to develop chemically-attenuated live viruses as vaccines for the prevention and treatment of DNA viral infections.
One of the most critical hurdles to developing CRISPR-based therapies for genetic disorders is the lack of effective delivery systems. To this end, this project aims todevelop a next-generation CRISPR delivery solution for fast and effective genome editing that supports the need for the CRISPR-based drug development market.